Abstract
Human γ-aminobutyric acid aminotransferase (GABA-AT), a pyridoxal phosphate dependent enzyme is responsible for the degradation of the inhibitory neurotransmitter GABA. Currently, GABA-AT is a potential drug target for epilepsy due to the selective inhibition in brain. In this computational study, we mainly focus on screening of novel lead candidates against GABA-AT using hexonic derivatives. Structure based virtual screening is performed in Vina that screened top hits based on least binding affinity. Further re-docking on hits is performed in AutoDock results in identification of leads with favorable binding energy and hydrogen bond interactions confirmed the effective inhibition. In conclusion, leads 3-aminohex-5-enoic acid and AG-E-60842 can acts as specific leads for GABA-AT and assist in discovery of novel anti-epileptic drugs.
Highlights
In mammalian central nervous system, -aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter that involved in modulation of central inhibitory tone via activation of various receptors like GABAA, GABAC (Osolodkin et al, 2009; Smith and Simpson, 2003)
Hit identification by virtual screening: For hit identification, structure-based virtual screening was performed in Vina software (Trott, Olson 2010) with hexonic derivatives targeting active sites of GABA-AT
We carried out homology modeling of human GABA-AT for inbuilt structure for inhibitor design
Summary
In mammalian central nervous system, -aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter that involved in modulation of central inhibitory tone via activation of various receptors like GABAA, GABAC (Osolodkin et al, 2009; Smith and Simpson, 2003). Ligand preparation: Twelve hexonic acid derivatives were selected as ligand dataset for inhibitor design. Hit identification by virtual screening: For hit identification, structure-based virtual screening was performed in Vina software (Trott, Olson 2010) with hexonic derivatives targeting active sites of GABA-AT.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
